Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 Mutations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04521686
Recruitment Status : Recruiting
First Posted : August 20, 2020
Last Update Posted : March 29, 2021
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Loxo Oncology, Inc.

Tracking Information
First Submitted Date  ICMJE August 13, 2020
First Posted Date  ICMJE August 20, 2020
Last Update Posted Date March 29, 2021
Actual Study Start Date  ICMJE October 16, 2020
Estimated Primary Completion Date February 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 18, 2020)
Recommended Phase 2 dose (RP2D) [ Time Frame: Up to 24 months ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: August 18, 2020)
  • Objective Response Rate [ Time Frame: Up to 24 months ]
  • Assess the safety and tolerability of LY3410738 when administered alone or in combination with cisplatin plus gemcitabine. [ Time Frame: Up to 24 months ]
  • To assess the preliminary anti-tumor activity of LY3410738 monotherapy and in combination with cisplatin plus gemcitabine [ Time Frame: Up to 24 months ]
  • Characterize PK properties of LY3410738 when administered alone or in combination with cisplatin plus gemcitabine. [ Time Frame: Up to 24 months ]
  • To characterize the pharmacodynamic properties of LY3410738 as expressed by change in 2-HG oncometabolite levels in plasma. [ Time Frame: Up to 24 months ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 Mutations
Official Title  ICMJE Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 Mutations
Brief Summary This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with IDH1 R132-mutant advanced solid tumor types, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma.
Detailed Description

This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with IDH1 R132-mutant advanced solid tumor types, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma.

This study includes 2 parts, Phase 1 dose escalation and Phase 1 dose expansion. The Phase 1 dose escalation monotherapy cohort will enroll any eligible patient with IDH1 R132-mutant advanced solid tumor. Once the LY3410738 monotherapy RP2D is established, Phase 1 dose expansion will begin and will include 4 cohorts to further evaluate safety and clinical activity - three cohorts will be administered LY3410738 monotherapy and the fourth cohort wiil administer LY3410738 to patients in combination with gemcitabine and cisplatin.

IDH1 R132 mutations will be identified through standard of care testing as routinely performed at each participating site utilizing material collected prior to patient consent . Molecular assays utilized for enrollment are required to be performed in CLIA, ISO/IEC, CAP, or other similarly certified laboratory. Enrollment of patients with cholangiocarcinoma, chondrosarcoma or glioma may be made based on molecular tests performed in either tumor or blood. Enrollment of patients with other tumor types is limited to testing performed in tumor tissue.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Cholangiocarcinoma
  • Chondrosarcoma
  • Glioma
  • Any Solid Tumor
Intervention  ICMJE Drug: LY3410738
Oral LY3410738
Study Arms  ICMJE Experimental: LY3410738
Phase 1 dose escalation - Multiple doses of LY3410738 Phase 1 dose expansion - The maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D)
Intervention: Drug: LY3410738
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: August 18, 2020)
180
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE September 2023
Estimated Primary Completion Date February 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Evidence of IDH1 R132 mutation in tumor tissue (any solid tumor) or circulating tumor DNA (cholangiocarcinoma, chondrosarcoma, and glioma) as determined by molecular testing routinely performed at a CLIA, ISO/IEC, CAP, or other similarly certified laboratory.
  2. Availability of an archived tumor tissue sample
  3. Eastern Cooperative Oncology Group (ECOG) 0-1
  4. At least 18 years of age
  5. Adequate organ function
  6. Ability to swallow capsules
  7. Ability to comply with outpatient treatment, laboratory monitoring, and required clinic visits for the duration of study participation
  8. For cholangiocarcinoma patients, must have adequate biliary drainage (per investigator's discretion), with no evidence of ongoing infection.
  9. Willingness of men and women of reproductive potential to observe conventional and effective birth control for the duration of treatment and for 3 months following the last dose of study treatment.

    Monotherapy Dose Escalation:

  10. A locally advanced or metastatic solid tumor, where standard curative or palliative measures are no longer effective or are not considered appropriate or safe in the opinion of the investigator.
  11. Measurable or non-measurable disease as determined by RECIST 1.1 or RANO as appropriate by tumor type.
  12. Prior IDH1 inhibitor treatment is permitted.

    Monotherapy Dose Expansion Cohort 1:

  13. Histologically or cytologically confirmed diagnosis of advanced or metastatic cholangiocarcinoma, following 1 to 2 lines of prior systemic treatment for advanced disease. Prior IDH1 inhibitor treatment is not permitted.
  14. Measurable disease as determined by RECIST 1.1.

    Monotherapy Dose Expansion Cohort 2:

  15. A locally advanced or metastatic solid tumor (except for cholangiocarcinoma), where standard curative or palliative measures are no longer effective or are not considered appropriate or safe in the opinion of the investigator.
  16. Measurable disease as determined by RECIST 1.1 or RANO as appropriate by tumor types.

    Monotherapy Dose Expansion Cohort 3:

  17. A locally advanced or metastatic solid tumor, where standard curative or palliative measures are no longer effective or are not considered appropriate or safe in the opinion of the investigator.
  18. Non-measurable disease only as determined by RECIST 1.1 or RANO as appropriate by tumor type.

    Combination Dose Expansion Cohort 4:

  19. Histologically or cytologically confirmed diagnosis of advanced or metastatic cholangiocarcinoma, not eligible for curative resection.
  20. No prior systemic therapy for advanced or metastatic disease with the following exceptions:

    • Patients who received adjuvant chemotherapy are eligible, if the adjuvant therapy was completed at least 6 months prior to the development of advanced or metastatic disease.
    • Patients who are receiving the first cycle of cisplatin plus gemcitabine as the first line systemic therapy while waiting for results of locally obtained molecule profiling including IDH1 mutational status, are eligible, provided that a radiographic assessment during screening demonstrates the absence of interval disease progression since initiation of chemotherapy treatment, and all other eligibility criteria are met.
  21. Measurable disease as determined by RECIST 1.1.

Exclusion Criteria:

  1. Had an investigational agent or anticancer therapy within 2 weeks; or investigational monoclonal antibody within 4 weeks prior to planned start of LY3410738.
  2. Had major surgery within 4 weeks prior to planned start of LY3410738.
  3. Had radiotherapy with a limited field of radiation for palliation within 7 days of the first dose of study treatment, except for patients receiving whole brain radiotherapy, which must be completed at least 4 weeks prior to the first dose of study treatment.
  4. Patients with cholangiocarcinoma: underwent hepatic radiation, chemoembolization and radiofrequency ablation, radioembolization or other locoregional therapy <4 weeks, have history of hepatic encephalopathy of any grade, have ascites requiring intervention such as diuretics or paracentesis, have ongoing cholangitis, have mixed hepatocellular biliary tract cancer histology
  5. Have active CNS metastases are not eligible. Patients with asymptomatic and treated brain metastases may participate provided that they are stable and are not requiring steroid treatment. Patients with suspected or confirmed leptomeningeal disease are not eligible even if treated.
  6. Have primary CNS tumors are eligible provided that they do not have leptomeningeal disease and are on a stable or decreasing steroid dose for 7 days prior to screening. Patients with evidence of intracranial hemorrhage either by MRI or CT are not eligible
  7. Any unresolved toxicities from prior therapy greater than CTCAE (version 5.0) Grade 2 at the time of starting study treatment except for alopecia.
  8. Have clinically significant, uncontrolled cardiac, cardiovascular disease or history of myocardial infarction within 6 months prior to planned start of study treatment.
  9. Have active uncontrolled systemic bacterial, viral, fungal or parasitic infection (except for fungal nail infection), or other clinically significant active disease process which in the opinion of the investigator and the sponsor makes it undesirable for the patient to participate in the trial. Screening for chronic conditions is not required.
  10. Known active hepatitis B virus (HBV). Note: Controlled (treated) hepatitis will be allowed if they meet the following criteria, antiviral therapy for HBV must be given for at least 1 month prior to first dose of study drug, and HBV viral load must be less than 2000 IU/ml (104 copies/ml) prior to the first dose of study drug. Those on active HBV therapy with viral loads under 2000 IU/ml (104 copies/ml) should stay on the same therapy throughout the study treatment (Appendix E).
  11. Known active hepatitis C virus (HCV). Note: Untreated patients with chronic infection by HCV are allowed on study. In addition, successfully treated patients (defined as sustained virologic response SVR12 or SVR24) are allowed, as long as there is 4 weeks between achieving sustained viral response (SVR12 or SVR24) and starting study drug.
  12. Known human immunodeficiency virus (HIV); excluded due to potential drug-drug interactions between anti-retroviral medications and LY3410738.
  13. Current treatment with certain strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers (Appendix F) and/or strong P-gp inhibitor (Appendix G).
  14. Treatment with proton pump inhibitor (PPIs) within 7 days of starting LY3410738 (Appendix H). For recommended alternatives, refer to Section 6.4.3.
  15. Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal absorption of the study drug.
  16. Active second malignancy unless in remission and with life expectancy > 2 years. Refer to protocol exclusion criteria (Section 4.2) for examples of allowed second malignancies.
  17. Pregnancy, lactation or plan to breastfeeding during the study or within 30 days of the last dose of study intervention.
  18. Patients with known hypersensitivity to any component of LY3410738 or its formulation.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Patient Advocacy 833-LOXO-IDH clinicaltrials@loxooncology.com
Listed Location Countries  ICMJE France,   Japan,   Korea, Republic of,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04521686
Other Study ID Numbers  ICMJE LOXO-IDH-20002
2020-002863-77 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Loxo Oncology, Inc.
Study Sponsor  ICMJE Loxo Oncology, Inc.
Collaborators  ICMJE Eli Lilly and Company
Investigators  ICMJE
Study Director: Thomas Xu Medical Monitor
PRS Account Loxo Oncology, Inc.
Verification Date September 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP